Company intelligence / Profile preview
Aceragen, Inc.
Durham, North Carolina, United Statesaceragen.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Aceragen has two main clinical programs: ACG-801 for Farber disease with planned registrational trial, and ACG-701 for cystic fibrosis pulmonary exacerbations and melioidosis with Phase 2 trials underway. The melioidosis program has received $51 million in funding from the Defense Threat Reduction Agency.
- Therapeutic areas
- PulmonologyRare DiseasesInfectious DiseasesRheumatology
- Modalities
- Small moleculesEnzyme replacement therapyBiologics
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Scriptr Global, Inc.NovaQuest Capital ManagementDefense Threat Reduction Agency
Beyond the preview
Go deeper on Aceragen, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aceragen, Inc..